drugset
drugset / Trial / NCT06862791

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

NCT06862791 ↗

Phase 2 Completed 377 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or overweight with at least one weight-related co-morbidity.

Timeline

Start
2025-02-18
Primary completion
2026-05-11
Completion
2026-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD6234 Small activating RNA (saRNA) — Subcutaneous
Subject AZD9550 Other / unclassified — Subcutaneous

Indications

obesity disorder